Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) ...

According to Zhen, the trial comparing nivolumab (Opdivo) plus chemotherapy vs chemotherapy alone led to an overall survival (OS) benefit in patients with a PD-L1 combined positive score (CPS) of 5 or ...

Impact of long-term chemotherapy (CTx) on outcomes in pancreatic ductal adenocarcinoma (PDAC): A real-world UK multi-centre study. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal ...

Phase III CheckMate -8HW trial shows the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improved progression-free survival and overall response rates in patients with ...

LAHORE: The Punjab government announced on Friday that those seeking assistance under the Nighaban Ramazan package should get themselves registered by Feb 15. It also announced that registration ...

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the FDA with priority review. The FDA accepted the biologics license ...

The present meta-analysis aimed to explore the efficacy and safety of the combination of nivolumab and ipilimumab in treating GI cancers. Methods: A systematic search of four databases (PubMed, Embase ...

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Squamous Cell Carcinoma does not have ...

Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase ...